Inomagen Therapeutics
Preclinical-stage biotechnology company developing a non-viral, catheter-delivered gene therapy approach that targets molecular mechanisms of atrial fibrillation. The organization combines target discovery, large-animal electrophysiology validation, a transvenous electroporation-based delivery method, and preparation for IND-enabling studies.
Industries
Nr. of Employees
small (1-50)
Inomagen Therapeutics
Products
Non-viral gene therapy program for atrial fibrillation
Preclinical gene therapy program using non-viral constructs to modify molecular drivers of atrial fibrillation and reduce electrical and structural remodeling in atrial tissue.
Transcatheter electroporation-based gene delivery system
A catheter-based delivery approach that uses reversible electroporation to facilitate localized gene transfer to the atrium, designed to be performed using workflows similar to catheter ablation.
Non-viral gene therapy program for atrial fibrillation
Preclinical gene therapy program using non-viral constructs to modify molecular drivers of atrial fibrillation and reduce electrical and structural remodeling in atrial tissue.
Transcatheter electroporation-based gene delivery system
A catheter-based delivery approach that uses reversible electroporation to facilitate localized gene transfer to the atrium, designed to be performed using workflows similar to catheter ablation.
Expertise Areas
- Cardiac gene therapy development
- Transcatheter gene delivery
- Preclinical large-animal electrophysiology
- Molecular target discovery for atrial fibrillation
Key Technologies
- Reversible electroporation (transvenous)
- Catheter-based endocardial delivery
- Naked plasmid DNA vectors
- shRNA-mediated gene silencing
News & Updates
Awarded second place at a cardiovascular innovation pitch competition recognizing development of a non-viral gene therapy for atrial fibrillation.
Awarded second prize among presenting life science companies for a non-viral gene therapy approach to atrial fibrillation.
Hosted a webinar presenting a single-dose, minimally invasive gene therapy approach for atrial fibrillation and preclinical results.
Awarded second place at a cardiovascular innovation pitch competition recognizing development of a non-viral gene therapy for atrial fibrillation.
Awarded second prize among presenting life science companies for a non-viral gene therapy approach to atrial fibrillation.
Hosted a webinar presenting a single-dose, minimally invasive gene therapy approach for atrial fibrillation and preclinical results.